Daohong Zhou, M.D., a professor of pharmacodynamics, has received multiple recent grants, including a multiple principal investigator R01 from the National Cancer Institute, alongside his longtime collaborator Guangrong Zheng, Ph.D., an associate professor of medicinal chemistry
The grant titled “Inhibition of Bcl-xL by Targeted Degradation” will carry out structure-activity relationship studies to improve the potency and safety profile of PROTAC based Bcl-xL degraders as potential treatment of T-cell acute lymphoblastic leukemia.
Zhou’s other recent awards include an NIH/NIA R56, an NIH/NIAID U19 and a CDMRP/DOD.